Skip to content
Fredun Pharmaceuticals logo

Fredun Pharmaceuticals

FREDUN NSE
₹1,508.70 +54.20 (+3.73%)
P/E
53.71
View as Markdown
MCP
Close 4 Nov 2026 ₹1,508.70 +514.90 +51.8% since 16 Jul 2026
Start ₹993.80

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
21.50%
Debt to Equity
0.80
EPS (TTM)
₹28.09
Book Value
₹200.11
Market Cap
—
P/E (TTM)
53.71
P/B
7.54
ROE
15.80%
Dividend Yield
0.05%
EBITDA
₹94.50 Cr
52W High
—
52W Low
—
Day Range
₹1,423.80 – ₹1,517.00
Volume
82,083

Peer Comparison

Healthcare › Pharmaceuticals

Fredun Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Fredun Pharmaceuticals (this company)
₹1,508.7053.71₹2,431 Cr7.540.05%15.80%21.50%₹748 Cr₹44 Cr
Median 8 companies₹1,641.0546.26₹1,25,337 Cr6.150.44%16.25%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

42 Weak

Data confidence 100/100

Category scores

Quality
50
Average
Returns, margins, earnings quality 22% weight
Valuation
30
Poor
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
32
Poor
Solvency, leverage, coverage 9% weight
Momentum
18
Poor
Trend strength, vol-adjusted 12% weight
Ownership
36
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 75.2% CAGR over last 5 years
  • Debtor days have improved from 87.9 to 53.2 days.
  • Company's median sales growth is 28.6% of last 10 years

Weaknesses

2
  • Stock is trading at 8.67 times its book value
  • Promoter holding has decreased over last 3 years: -4.74%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish298
OscillatorsNeutral252
Moving AveragesStrong Bullish046

Key readings

RSI (14)
57.66
Neutral
MACD (12,26,9)
12.97
Bullish
SMA (50)
1,423.00
Bullish
SMA (200)
—
Neutral

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+31.21%
5Y+36.50%
3Y+32.17%
1Y+39.87%
TTM+50.30%

Net profit

Net profit growth by window
10Y+41.86%
5Y+75.18%
3Y+44.22%
1Y+57.14%
TTM+91.30%

Operating cash flow

Operating cash flow growth by window
10Y+18.22%
5YZero base
3YTurned positive
1YTurned positive
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+4.81 pp
5Y+8.36 pp
3Y+4.15 pp
1Y+2.66 pp
TTM+2.46 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹57.00 Cr
Mar 2018₹60.00 Cr
Mar 2019₹97.00 Cr
Mar 2020₹113 Cr
Mar 2021₹134 Cr
Mar 2022₹222 Cr
Mar 2023₹275 Cr
Mar 2024₹348 Cr
Mar 2025₹454 Cr
Mar 2026₹635 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹1.00 Cr
Mar 2018₹2.00 Cr
Mar 2019₹4.00 Cr
Mar 2020₹2.00 Cr
Mar 2021₹2.00 Cr
Mar 2022₹6.00 Cr
Mar 2023₹11.00 Cr
Mar 2024₹16.00 Cr
Mar 2025₹21.00 Cr
Mar 2026₹33.00 Cr

Quarterly Results

₹ Cr
539730 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
62
82
87
118
79
107
103
167
120
145
161
213
228
Expenses
54
72
76
107
68
93
89
150
103
123
135
184
195
Operating Profit
8
10
11
11
10
14
13
17
17
22
26
29
33
OPM %
12%
12%
12%
9%
13%
13%
13%
10%
14%
15%
16%
14%
14%
Other Income
0
0
0
0
0
0
0
0
0
0
0
0
0
Interest
3
3
4
4
4
5
5
8
7
8
11
14
9
Depreciation
1
1
1
1
1
1
1
1
1
2
2
3
4
PBT
4
6
6
6
6
8
7
8
9
13
14
12
21
Tax %
41%
32%
27%
13%
25%
44%
25%
12%
25%
25%
25%
4%
36%
Net Profit
2
4
4
5
4
4
5
7
7
10
10
11
13
EPS (₹)
1.75
2.79
2.99
3.59
2.91
3.01
3.75
4.98
4.77
6.85
6.51
6.75
7.98

Profit & Loss

₹ Cr
539730 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
25
42
57
60
97
113
134
222
275
348
454
635
748
Expenses
24
38
53
54
87
104
126
208
247
310
401
544
637
Operating Profit
2
4
3
6
10
8
8
14
28
38
53
91
111
OPM %
7%
9%
6%
10%
11%
7%
6%
6%
10%
11%
12%
14%
15%
Other Income
0
1
2
0
0
1
1
2
2
1
2
4
0
Interest
1
2
2
2
3
4
4
5
9
14
22
39
41
Depreciation
1
1
1
1
1
2
2
2
3
4
4
8
10
PBT
1
2
2
3
6
2
3
9
18
21
28
48
59
Tax %
52%
42%
36%
34%
28%
24%
37%
26%
38%
27%
26%
30%
—
Net Profit
0
1
1
2
4
2
2
6
11
16
21
33
44
EPS (₹)
0.37
1.51
2.01
1.7
3.72
1.58
1.68
4.77
7.95
11.08
14.65
20.25
28.09
Div. Payout %
0%
13%
10%
12%
6%
14%
14%
5%
3%
2%
2%
1%
—

Balance Sheet

₹ Cr
539730 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2
2
3
4
4
4
4
5
5
5
5
Reserves
0
1
2
19
35
37
39
64
92
117
137
273
Borrowings
9
16
21
10
19
35
40
53
87
106
166
222
Other Liabilities
11
24
30
47
47
65
79
66
74
81
179
141
Total Liabilities
23
43
56
79
105
141
162
187
257
308
487
642
Fixed Assets
8
15
16
16
31
31
30
32
39
47
53
118
CWIP
1
0
4
11
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
1
2
2
Other Assets
14
29
36
52
74
110
131
155
218
260
433
522
Total Assets
23
43
56
79
105
141
162
187
257
308
487
642

Cash Flow

₹ Cr
539730 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
2
3
4
17
1
−11
0
−2
−14
0
−21
16
Investing
−3
−6
−7
−8
−5
−1
−1
−4
−9
−8
−6
−74
Financing
1
3
3
−8
4
14
−1
7
25
6
26
122
Net Cash Flow
0
1
−1
1
0
2
−2
1
1
−2
−1
65
Free Cash Flow
−1
−3
−3
9
−4
−12
−1
−7
−24
−8
−27
−57
CFO/OP
108
85
117
303
8
−128
2
−17
−52
−1
−43
18

Ratios

539730 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
75
98
131
94
67
126
112
148
46
68
142
53
Inventory Days
102
140
68
170
249
227
242
96
264
246
267
219
Days Payable
167
221
224
360
205
208
215
101
104
88
161
71
Cash Conversion Cycle
11
17
−24
−96
110
145
139
144
205
225
248
201
Working Capital Days
−54
−44
−39
42
66
65
116
126
97
92
76
79
ROCE %
14%
25%
18%
16%
21%
10%
10%
13%
18%
17%
19%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Fredun Pharmaceuticals insights

67 extracted metrics across FY07–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 43.62%
  • Public 43.24%
  • Others 9.01%
  • DIIs 3.44%
  • FIIs 0.69%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Fredun Pharmaceuticals

What does Fredun Pharmaceuticals Ltd do?
Incorporated in 1987, Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals products
Where is Fredun Pharmaceuticals Ltd (FREDUN) listed?
Fredun Pharmaceuticals Ltd trades as FREDUN on the NSE and under code 539730 on the BSE.
Which sector does Fredun Pharmaceuticals Ltd belong to?
Fredun Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd trades at a PE ratio of 53.71 as of 4 Nov 2026, on earnings per share of ₹28.09, against a book value of ₹200.11 per share.
Does Fredun Pharmaceuticals Ltd pay dividends?
Fredun Pharmaceuticals Ltd has a dividend yield of 0.05%.
What is the Return on Equity (ROE) of Fredun Pharmaceuticals Ltd?
Fredun Pharmaceuticals Ltd reported a return on equity of 15.80%. Its debt-to-equity ratio is 0.80.

Company Information

Incorporated in 1987, Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals products

Website fredungroup.com
Listed 28 Mar 2016
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/539730.md for Fredun Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month